trial
as of 2026-07-01Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
NCTId NCT03121586
at a glance
Phase 3 · Terminated
Enrollment 995 (actual)
Sponsored by ACADIA Pharmaceuticals Inc.
Primary completion 2024-04-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Terminated
Enrollment
995 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2017-01
Primary completion
2024-04-30
Eligibility
ALL · 18 Years
Interventions & indications
Drugs
Indications
Sponsors
ACADIA Pharmaceuticals Inc.Lead Sponsor
Sites
161 total
Phoenix, United StatesLittle Rock, United StatesRogers, United StatesBellflower, United StatesCulver City, United StatesLemon Grove, United StatesSan Diego, United StatesSanta Ana, United StatesTorrance, United StatesHialeah, United StatesLauderhill, United StatesMiami, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
995
Phase
PHASE3
Primary Completion Date
2024-04-30
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication